Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Orv Hetil ; 157(7): 268-74, 2016 Feb 14.
Artículo en Húngaro | MEDLINE | ID: mdl-26853728

RESUMEN

INTRODUCTION: Self-expandable metal and plastic stents can be applied in the palliative endoscopic treatment of patients with unresectable malignant biliary obstruction. The use of metal stentsis recommended if the patient's life expectancy is more than four months. AIM: To compare the therapeutic efficacy and cost-effectiveness of metal and plastic stents in the treatment of malignant biliary obstruction. METHOD: The authors retrospectively enrolled patients who received metal (37 patients) or plastic stent (37 patients). The complication rate, stent patency and cumulative cost of treatment were assessed in the two groups. RESULTS: The complication rate of metal stents was lower (37.84% vs. 56.76%), but the stent patency was higher compared with plastic stents (19.11 vs. 8.29 weeks; p = 0.0041). In the plastic stent group the frequency of hospitalization of patients in context with stent complications (1.18 vs. 2.32; p = 0.05) and the necessity of reintervention for stent dysfunction (17 vs. 27; p = 0.033) were substantially higher. In this group multiple stent implantation raised the stent patency from 7.68 to 10.75 weeks. There was no difference in the total cost of treatment of malignant biliary obstruction between the two groups (p = 0.848). CONCLUSIONS: Considering the cost of treatment and the burden of patients the authors recommend self-expandable metal sten timplantation if the life expectancy of patients is more than two months. In short survival cases multiple plastic stent implantation is recommended.


Asunto(s)
Neoplasias del Sistema Biliar/complicaciones , Procedimientos Quirúrgicos del Sistema Biliar/economía , Procedimientos Quirúrgicos del Sistema Biliar/métodos , Colestasis/etiología , Stents Metálicos Autoexpandibles/economía , Stents/economía , Adulto , Anciano , Anciano de 80 o más Años , Colangiopancreatografia Retrógrada Endoscópica , Colestasis/diagnóstico por imagen , Análisis Costo-Beneficio , Femenino , Humanos , Hungría , Masculino , Persona de Mediana Edad , Cuidados Paliativos/economía , Cuidados Paliativos/métodos , Plásticos , Estudios Retrospectivos
2.
Orv Hetil ; 157(14): 523-8, 2016 Apr 03.
Artículo en Húngaro | MEDLINE | ID: mdl-27017851

RESUMEN

In the last couple of years incretin-based antidiabetic drugs became increasingly popular and widely used for treating patients with type 2 diabetes. Immediately after launching, case reports and small case series were published on the potential side effects of the new drugs, with special attention to pancreatic disorders such as acute pancreatitis or pancreatic cancer. As clinical observations accumulated, these side-effects were noted with nearly all drugs of this class. Although these side-effects proved to be rare, an intensive debate evolved in the literature. Opinion of diabetes specialists and representatives of pharmaceutical industry as well as position statements of different international scientific boards and health authorities were published. In addition, results of randomized clinical trials with incretin-based therapy and meta-analyses became available. Importantly, in everyday clinical practice, the label of the given drug should be followed. With regards to incretins, physicians should be cautious if pancreatitis in the patients' past medical history is documented. Early differential diagnosis of any abdominal pain during treatment of incretin-based therapy should be made and the drug should be discontinued if pancreatitis is verified. Continuous post-marketing surveillance and side-effect analysis are still justified with incretin-based antidiabetic treatment in patients with type 2 diabetes.


Asunto(s)
Dolor Abdominal/etiología , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/efectos adversos , Incretinas/efectos adversos , Neoplasias Pancreáticas/inducido químicamente , Neoplasias Pancreáticas/diagnóstico , Pancreatitis/inducido químicamente , Pancreatitis/diagnóstico , Enfermedad Aguda , Diagnóstico Diferencial , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/diagnóstico , Humanos , Hipoglucemiantes/administración & dosificación , Incretinas/administración & dosificación , Metaanálisis como Asunto , Neoplasias Pancreáticas/complicaciones , Pancreatitis/complicaciones , Ensayos Clínicos Controlados Aleatorios como Asunto , Factores de Riesgo
3.
Orv Hetil ; 163(44): 1735-1742, 2022 10 30.
Artículo en Húngaro | MEDLINE | ID: mdl-36309887

RESUMEN

Pancreatic lipid accumulation - which is known as NAFPD (non-alcoholic fatty pancreas disease) - has gained an increasing attention in the last couple of years. Previously, this alteration was mentioned using different names. Undoubtedly, the term of NAFPD is still rarely used in the Hungarian scientific literature, even the proper translation should be considered difficult. Pancreatic lipid accumulation is a clinical manifestation of ectopic occurrence of adipose tissue. NAFPD can be diagnosed by different imaging modalities. Although proper quantification of pancreatic lipid accumulation is challenging, ultrasonography and computed tomography are used in clinical practice. The prevalence of NAFPD was about 30-35% in different adult populations but a relatively higher frequency might also be observed in children and adolescents with obesity. NAFPD may influence both endocrine and exocrine functions of the pancreas. Clinical studies documented a close correlation between NAFPD and type 2 diabetes/metabolic syndrome. Local consequences of pancreatic lipid accumulation are less recognized but clinical observations suggested that NAFPD might play a role in the development of acute and chronic pancreatitis, pancreatic cancer, and pancreatic exocrine dysfunction. Therapeutically, weight loss in patients with obesity, due to life-style modification, pharmacological intervention or bariatric surgery, may reduce pancreatic lipid accumulation. Importantly, antihyperglycemic treatment of patients with type 2 diabetes should be performed by using antidiabetic drugs providing not only proper glycaemic control but even weight loss. NAFPD is a relatively new clinical entity which is rather common and probably underdiagnosed. Basic and new data about NAFPD are of importance for clinicians working in the field of different specialties and sub-specialties (internal medicine, gastroenterology, diabetology, lipidology, obesitology, surgery). Orv Hetil. 2022; 163(44): 1735-1742.


Asunto(s)
Diabetes Mellitus Tipo 2 , Síndrome Metabólico , Enfermedades Pancreáticas , Niño , Humanos , Adolescente , Enfermedades Pancreáticas/diagnóstico , Enfermedades Pancreáticas/epidemiología , Síndrome Metabólico/epidemiología , Páncreas , Obesidad/complicaciones , Lípidos , Pérdida de Peso
4.
Magy Seb ; 64(4): 189-92, 2011 Aug.
Artículo en Húngaro | MEDLINE | ID: mdl-21835734

RESUMEN

The authors emphasize that late results following surgery for pancreatic cancer can be improved by increasing the rate of R0 resections. Therefore, they propose a new method for pancreatic head resection, which starts with the dissection of the uncinate process and continues in a caudo-cranial direction (retrograde). Thus the superior mesenteric artery comes into view at the beginning, and the peripancreatic tissues can be removed completely along the vessel consequently. This method can potentially decrease the risk of the bleeding and major vessel injury. The authors carried out six pancreatic head resections with the technique mentioned above, and histology revealed R0 resection in all six cases. Non-traditional, retrograde dissection of the pancreatic head is a recommended method which is supported by literature data as well as the authors' own experience.


Asunto(s)
Pancreatectomía , Pancreaticoduodenectomía , Humanos , Arteria Mesentérica Superior , Páncreas , Neoplasias Pancreáticas/cirugía
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda